Radiogenomics aims to identify potential associations between clinical imaging and
cellular and molecular profiling to characterize disease phenotypes.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Clinical RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Behind the numbers: decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations.Radiology. 2014; 270: 320-325
- The 2016 World Health Organization classification of tumors of the central nervous system: a summary.Acta Neuropathol (Berl). 2016; 131: 803-820
- Shedding light on the 2016 World Health Organization classification of tumors of the central nervous system in the era of radiomics and radiogenomics.Magn Reson Imaging Clin N Am. 2016; 24: 741-749
- Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.Proc Natl Acad Sci U S A. 2008; 105: 5213-5218
- MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.Radiology. 2013; 267: 560-569
- Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation.Radiology. 2013; 270: 1-2
- Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.Radiology. 2014; 272: 484-493
- A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma.J Neurosurg. 2016; 124: 1008-1017
- Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.PLoS One. 2011; 6: e25451
- Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features.Radiology. 2015; 276: 313
- Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.Anticancer Res. 2009; 29: 4845-4854
- Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.Oncology. 2010; 78: 103-114
- Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.AJNR Am J Neuroradiol. 2011; 32: 882-889
- MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.J Clin Oncol. 2008; 26: 2192-2197
- Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study.Oncotarget. 2016; 7: 55377-55394
- IDH1 and IDH2 mutations in gliomas.N Engl J Med. 2009; 360: 765-773
- The 2016 World Health Organization classification of tumours of the central nervous system.Presse Med. 2018; 47: e187-e200
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.J Neurooncol. 2012; 107: 197-205
- Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.J Clin Invest. 2013; 123: 3659-3663
- Cancer statistics, 2010.CA Cancer J Clin. 2010; 60: 277-300
- Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results.Radiology. 2012; 264: 387-396
- Non-small cell lung cancer radiogenomics map identifies relationships between molecular and imaging phenotypes with prognostic implications.Radiology. 2018; 286: 307-315
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.Lancet Oncol. 2011; 12: 1004-1012
- ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.Radiology. 2014; 272: 568-576
- Radiologic characteristics of surgically resected non-small cell lung cancer with ALK rearrangement or EGFR mutations.Ann Thorac Surg. 2016; 101: 473-480
- EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Int J Med Sci. 2013; 10: 320-330
- CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung.AJR Am J Roentgenol. 2015; 205: 1016-1025
- CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma.Radiology. 2016; 280: 271-280
- Non-small cell lung cancer with resistance to EGFR-TKI therapy: CT characteristics of T790M mutation-positive cancer.Radiology. 2018; 289: 227-237
- Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.J Thorac Imaging. 2014; 29: 357-363
- Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: imaging features and histological subtypes.Eur Radiol. 2016; 26: 3660-3668
- Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer.Cancer Res. 2012; 72: 3725-3734
- Epithelial-mesenchymal transitions: twist in development and metastasis.Cell. 2004; 118: 277-279
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.Oncogene. 2010; 29: 4741-4751
- Radiogenomic analysis demonstrates associations between (18)F-fluoro-2-deoxyglucose PET, prognosis, and epithelial-mesenchymal transition in non-small cell lung cancer.Radiology. 2016; 280: 261-270
- Genomic adequacy from solid tumor core needle biopsies of ex vivo tissue and in vivo lung masses: prospective study.Radiology. 2016; 282: 903-912
- Radiomics and radiogenomics of primary liver cancers.Clin Mol Hepatol. 2018; 25: 21-29
- 2017 version of LI-RADS for CT and MR imaging: an update.Radiographics. 2017; 37: 1994-2017
- Decoding global gene expression programs in liver cancer by noninvasive imaging.Nat Biotechnol. 2007; 25: 675-680
- Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma.J Vasc Interv Radiol. 2007; 18: 821-830
- Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.Eur Radiol. 2017; 27: 4472-4481
- A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma.Hepatology. 2015; 62: 792-800
- Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study.J Med Imaging (Bellingham). 2017; 4: 041303
- Texture analysis of baseline multiphasic hepatic computed tomography images for the prognosis of single hepatocellular carcinoma after hepatectomy: a retrospective pilot study.Eur J Radiol. 2017; 90: 198-204
- CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma.Abdom Radiol. 2017; 42: 1695-1704
- Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma?.Radiology. 2016; 279: 432-442
- Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients.BMC Cancer. 2018; 18 (Available at:): 1148
- Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.Br J Cancer. 2008; 98: 418-425
- Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma.Am J Gastroenterol. 2010; 105: 1123-1132
- Cholangiocarcinoma: correlation between molecular profiling and imaging phenotypes.PLoS One. 2015; 10: e0132953
- CT/MRI in staging renal cell carcinoma.Cancer Imaging. 2004; 4 Spec No A: S25-S32
- Advanced renal cell carcinoma: role of the radiologist in the era of precision medicine.Radiology. 2017; 284: 333-351
- Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.J Clin Oncol. 2008; 26: 127-131
- Radiogenomics of clear-cell renal cell carcinoma: associations between CT imaging features and mutations.Radiology. 2014; 270: 464-471
- Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.Eur Urol. 2013; 63: 848-854
- Multilocular cystic renal cell carcinoma: comparison of imaging and pathologic findings.AJR Am J Roentgenol. 2012; 198: W20-W26
- The radiogenomic risk score: construction of a prognostic quantitative, noninvasive image-based molecular assay for renal cell carcinoma.Radiology. 2015; 277: 114-123
- Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.J Clin Oncol. 2009; 27: 4076-4081
- The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.Eur Radiol. 2016; 26: 2798-2807
- Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: a review.JAMA Oncol. 2019; 5: 411-421.
- Adult renal cell carcinoma: a review of established entities from morphology to molecular genetics.Surg Pathol Clin. 2015; 8: 587-621
- Eble J. Epstein J. Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs. WHO classification of tumours. 1st edition. IARC, Lyon (France)2004: 359
- Renal medullary carcinoma the seventh sickle cell nephropathy.Am J Surg Pathol. 1995; 19: 1-11
- Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States.Urol Oncol. 2015; 33: 164.e11-7
- Delay of surgery in men with low risk prostate cancer.J Urol. 2011; 185: 2143-2147
- PI-RADS prostate imaging - reporting and data system: 2015, version 2.Eur Urol. 2016; 69: 16-40
- A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.Eur Urol. 2014; 66: 550-560
- Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.Oncotarget. 2016; 7: 33855-33865
- Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Oncotarget. 2016; 7: 53362-53376
- Multiregional radiogenomic assessment of prostate microenvironments with multiparametric MR imaging and DNA whole-exome sequencing of prostate glands with adenocarcinoma1.Radiology. 2017; 284: 109-119
- Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.JAMA. 2015; 313: 390-397
- Entering an era of radiogenomics in prostate cancer risk stratification.Transl Androl Urol. 2018; 7: S443-S452
- Concordance of BI-RADS assessments and management recommendations for breast MRI in community practice.AJR Am J Roentgenol. 2016; 206: 211-216
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A. 2001; 98: 10869-10874
- Gene expression profiling predicts clinical outcome of breast cancer.Nature. 2002; 415: 530-536
- Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape.AJR Am J Roentgenol. 2012; 199: 654-663
- Breast cancer: radiogenomic biomarker reveals associations among dynamic contrast-enhanced MR imaging, long noncoding RNA, and metastasis.Radiology. 2015; 275: 384-392
- MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, oncotype DX, and PAM50 gene assays.Radiology. 2016; 281: 382-391
- Qualitative radiogenomics: association between oncotype DX test recurrence score and BI-RADS mammographic and breast MR imaging features.Radiology. 2018; 286: 60-70
- MRI phenotype of breast cancer: kinetic assessment for molecular subtypes.J Magn Reson Imaging. 2015; 42: 920-924
- Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.Radiology. 2014; 273: 365-372
- Histogram analysis of apparent diffusion coefficient at 3.0t: correlation with prognostic factors and subtypes of invasive ductal carcinoma.J Magn Reson Imaging. 2015; 42: 1666-1678
- Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.J Magn Reson Imaging. 2015; 41: 175-182
- Correlations between diffusion-weighted imaging and breast cancer biomarkers.Eur Radiol. 2012; 22: 1519-1528
- Magnetic resonance imaging texture analysis classification of primary breast cancer.Eur Radiol. 2016; 26: 322-330
- Computational approach to radiogenomics of breast cancer: luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms.J Magn Reson Imaging. 2015; 42: 902-907
- Breast cancer molecular subtype classifier that incorporates MRI features.J Magn Reson Imaging. 2016; 44: 122-129
- Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.Radiology. 2014; 272: 374-384
- A multichannel Markov random field framework for tumor segmentation with an application to classification of gene expression-based breast cancer recurrence risk.IEEE Trans Med Imaging. 2013; 32: 637-648
- Diffusion magnetic resonance imaging: a molecular imaging tool caught between hope, hype and the real world of “personalized oncology.World J Radiol. 2017; 9: 253-268
- Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences.Immunol Rev. 2017; 280: 249-279
- Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.Radiology. 2005; 234: 961-967
- Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-Met inhibition.Radiology. 2016; 279: 103-117
- Oncogenesis: an “off-target” effect of radiofrequency ablation.Radiology. 2015; 276: 426-432
- Systemic siRNA nanoparticle-based drugs combined with radiofrequency ablation for cancer therapy.PLoS One. 2015; 10: e0128910
- Targeting STAT3 to suppress systemic pro-oncogenic effects from hepatic radiofrequency ablation.Radiology. 2017; 286: 524-536
- Image-guided biopsy in the era of personalized cancer care: proceedings from the society of interventional radiology research consensus panel.J Vasc Interv Radiol. 2016; 27: 8-19
Article info
Publication history
Published online: May 29, 2019
Footnotes
Disclosure Statement: No disclosures.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
